{"DataElement":{"publicId":"3534688","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes and no indicator related to patient receiving treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells, as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3534679v1.0:3506068v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3534679","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"Information related to patient receiving treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells, as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2233604v1.0:3534677v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3534677","version":"1","preferredName":"Antibody Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"Treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C15542:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody Therapy","conceptCode":"C15542","definition":"Treatment with injections of antibodies to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2BD9-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2BEA-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6162769","version":"1","longName":"University of Rochester","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6337044","version":"1","longName":"URCC Forms","context":"NCIP"}]}],"AlternateNames":[{"name":"3534679v1.0:3506068v1.0","type":"USED_BY","context":"CITN"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NCIP","type":"USED_BY","context":"NCIP"}],"ReferenceDocuments":[{"name":"At least 12 weeks from comple","type":"Preferred Question Text","description":"At least 12 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-CTLA4 and anti-PD1","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior treatment with anti-CTLA-4 or experimental check point inhibitor such as anti-PD1","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies (e.g., anti-CTLA4, anti-PD1, anti-PD-L1)","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"At least 4 weeks from completion of antibody therapy with anti-checkpoint antibodies (e.g., anti-CTLA4 and anti-PD1, anti-PD-L1)","url":null,"context":"CTEP"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Has it been a minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization?","url":null,"context":"CTEP"},{"name":"URCC21038","type":"Alternate Question Text","description":"Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy according to FDA labels or NCCN guidelines at Category 1 or 2A as standard of care treatment alone or in combination with co-treatments (including alternative ICIs)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2C6B-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"HARTLEYG","dateModified":"2022-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}